Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial-MedSci.cn

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

Xu, BH; Zhang, QY; Sun, T; Li, W; Teng, Y; Hu, XC; Bondarenko, I; Adamchuk, H; Zhang, LM; Trukhin, D; Wang, SS; Zheng, H; Tong, ZS; Shparyk, Y; Wang, QY

Xu, BH (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Med Oncol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China.

BIODRUGS, 2021; 35 (3): 337

Abstract

Background HLX02 is an approved biosimilar of trastuzumab. Objective This study aimed to evaluated the efficacy, safety, and immunogenicity of HLX02 c......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

科室

工具

服务